Baxter has acquired SuppreMol for EUR 200 million (approximately $225M USD) before working capital and other adjustments.
SuppreMol is a privately held biopharmaceutical company based in Martinsried, Germany developing treatment options for autoimmune and allergic diseases.
|Searching for more deal information? Current Partnering offers the following options:
The acquisition includes SuppreMol’s early-stage development portfolio of novel biologic immunoregulatory therapeutics for the treatment of autoimmune diseases, focusing on the modulation of Fc receptor signaling pathways, an immune target that could have broad applications in autoimmune disorders.
In addition to the portfolio, Baxter also acquires and will continue to operate SuppreMol’s operations in Munich.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies